Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 14/20 | 0.71 |
| ▸ | RXRA | P19793 | 5/20 | 0.69 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.63 |
| ▸ | MAPT | P10636 | 3/20 | 0.63 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.63 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.63 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.63 |
| ▸ | EGFR | P00533 | 1/20 | 0.63 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.63 |
| ▸ | DRD1 | P21728 | 1/20 | 0.63 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.63 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.63 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.63 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.63 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.63 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.63 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.63 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.63 |
| ▸ | CYSLTR1 | Q9Y271 | 1/20 | 0.63 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6936351 | 1.00 | PPARG (0.71) | PPARGRXRACYP1A2MAPTMAPK1 | |
| SCHEMBL6938658 | 1.00 | PPARG (0.71) | PPARGRXRACYP1A2MAPTMAPK1 | |
| SCHEMBL8149963 | 0.99 | PPARG (0.69) | PPARGRXRACYP1A2MAPTMAPK1 | |
| SCHEMBL8330334 | 0.93 | PPARG (0.64) | PPARGRXRACYP1A2MAPTMAPK1 | |
| SCHEMBL8330337 | 0.93 | PPARG (0.64) | PPARGRXRACYP1A2MAPTMAPK1 | |
| SCHEMBL8330341 | 0.93 | PPARG (0.64) | PPARGRXRACYP1A2MAPTMAPK1 | |
| SCHEMBL19862425 | 0.92 | PPARG (0.72) | PPARGRXRACYP1A2MAPTMAPK1 | |
| SCHEMBL17819202 | 0.91 | PPARG (0.71) | PPARGRXRACYP1A2MAPTMAPK1 | |
| SCHEMBL17819199 | 0.91 | PPARG (0.71) | PPARGRXRACYP1A2MAPTMAPK1 | |
| SCHEMBL6934000 | 0.90 | PPARG (0.57) | PPARGRXRACYP1A2MAPTMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6121321-A | IN CARRIER | CELL PATHWAYS, INC. (US) | 2000-09-19 | — | — | US | claimed |
| US-5998477-A | MIXTURE OF DRUG AND CARRIER | CELL PATHWAYS INC. (US) | 1999-12-07 | — | — | US | claimed |
| WO-1997047295-A1 | SUBSTITUTED METHOXY BENZYLIDENE INDENYL-ACETIC AND PROPIONIC ACIDS FOR TREATING PATIENTS WITH PRECANCEROUS LESIONS | CELL PATHWAYS, INC. (US) | 1997-12-18 | — | — | WO | claimed |
| US-12479813-B2 | Method of therapeutically treating cancer | ADT PHARMACEUTICALS, LLC (US) | 2025-11-25 | — | — | US | disclosed |
| US-11834404-B2 | Derivatives of sulindac can protect normal cells against oxidative damage | UNIVERSITY OF SOUTH ALABAMA (US) | 2023-12-05 | — | — | US | disclosed |
| EP-3233794-B1 | INDENYL COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND MEDICAL USES THEREOF | ADT PHARMACEUTICALS LLC (US) | 2023-02-01 | — | — | EP | disclosed |
| US-20220315553-A1 | INDENYL COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND MEDICAL USES THEREOF | ADT PHARMACEUTICALS, LLC (US) | 2022-10-06 | — | — | US | disclosed |
| EP-4053105-A1 | INDENYL COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND MEDICAL USES THEREOF | ADT Pharmaceuticals, LLC (US) | 2022-09-07 | — | — | EP | disclosed |
| US-11407727-B2 | Indenyl compounds, pharmaceutical compositions, and medical uses thereof | ADT PHARMACEUTICALS, LLC (US) | 2022-08-09 | — | — | US | disclosed |
| US-20220106250-A1 | DERIVATIVES OF SULINDAC CAN PROTECT NORMAL CELLS AGAINST OXIDATIVE DAMAGE | UNIVERSITY OF SOUTH ALABAMA (US) | 2022-04-07 | — | — | US | disclosed |
| US-11186534-B2 | Derivatives of sulindac can protect normal cells against oxidative damage | UNIVERSITY OF SOUTH ALABAMA (US) | 2021-11-30 | — | — | US | disclosed |
| EP-0910380-A4 | SUBSTITUTED BENZYLIDENE INDENYL FORMAMIDES, ACETAMIDES AND PROPIONAMIDES | CELL PATHWAYS INC (US) | 2000-09-27 | — | — | EP | disclosed |
| US-6121321-A | IN CARRIER | CELL PATHWAYS, INC. (US) | 2000-09-19 | — | — | US | disclosed |
| US-6063818-A | Substituted benzylidene indenyl formamides, acetamides and propionamides | CELL PATHWAYS INC. (US) | 2000-05-16 | — | — | US | disclosed |
| US-6028116-A | Substituted condensation products of 1H-indenyl-hydroxyalkanes with aldehydes for neoplasia | CELL PATHWAYS, INC. (US) | 2000-02-22 | — | — | US | disclosed |
| US-5998477-A | MIXTURE OF DRUG AND CARRIER | CELL PATHWAYS INC. (US) | 1999-12-07 | — | — | US | disclosed |
| US-5965619-A | ADMINISTERING AN INDENE DERIVATIVE OF GIVEN FORMULA, SUCH AS 1-(2,4,6-TRIMETHOXYBENZYLIDENE)-5-DIMETHYLAMINO-2-METHYL-3-INDENYL ACETIC ACID, TO TREAT PRECANCEROUS LESIONS SUCH AS COLONIC ADENOMATOUS POLYPS; SIDE EFFECT REDUCTION | CELL PATHWAYS INC. (US) | 1999-10-12 | — | — | US | disclosed |
| EP-0910380-A1 | SUBSTITUTED BENZYLIDENE INDENYL FORMAMIDES, ACETAMIDES AND PROPIONAMIDES | Cell Pathways, Inc. (US) | 1999-04-28 | — | — | EP | disclosed |
| WO-1997047303-A1 | SUBSTITUTED BENZYLIDENE INDENYL FORMAMIDES, ACETAMIDES AND PROPIONAMIDES | CELL PATHWAYS, INC. (US) | 1997-12-18 | — | — | WO | disclosed |
| WO-1997047295-A1 | SUBSTITUTED METHOXY BENZYLIDENE INDENYL-ACETIC AND PROPIONIC ACIDS FOR TREATING PATIENTS WITH PRECANCEROUS LESIONS | CELL PATHWAYS, INC. (US) | 1997-12-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220315553-A1 | INDENYL COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND MEDICAL USES THEREOF | INSRR, INSR, BRCA1 | PPARG 2965/4885RXRA 124/4885CYP1A2 366/4885 |
| US-11834404-B2 | Derivatives of sulindac can protect normal cells against oxidative damage | PRDX3, PRDX5, SQOR | PPARG 448/4885RXRA 1343/4885CYP1A2 1405/4885 |
| US-12479813-B2 | Method of therapeutically treating cancer | RECQL, RDX, RNASE1 | PPARG 1690/4885RXRA 40/4885CYP1A2 3746/4885 |
| US-11407727-B2 | Indenyl compounds, pharmaceutical compositions, and medical uses thereof | INSRR, INSR, BRCA1 | PPARG 2965/4885RXRA 124/4885CYP1A2 366/4885 |
| US-20220106250-A1 | DERIVATIVES OF SULINDAC CAN PROTECT NORMAL CELLS AGAINST OXIDATIVE DAMAGE | PRDX3, PRDX5, SQOR | PPARG 448/4885RXRA 1343/4885CYP1A2 1405/4885 |
| US-11186534-B2 | Derivatives of sulindac can protect normal cells against oxidative damage | PRDX3, PRDX5, SQOR | PPARG 448/4885RXRA 1343/4885CYP1A2 1405/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.